Pyridostigmine Bromide

Global Calcium is one of the leading manufacturers and exporters of Pyridostigmine Bromide CAS no. 101-26-8, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Pyridostigmine Bromide we hereby state the following facts about the drug:

Indications for Use

The drug is indicated for the treatment of myasthenia gravis.

Drug Information

Myasthenia gravis: Pyridostigmine is a FDA approved treatment for myasthenia gravis. Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction. It is indicated for the reversal or antagonism of the neuromuscular blocking effects of nondepolarizing muscle relaxants. The lack of acetylcholine signalling leads to muscle tone loss, muscle weakness, and fatigue.

Congenital myasthenic syndromes (CMS): It is a common first-line treatment in CMS, of which there are multiple subtypes caused by mutations in more than 30 distinct genes. However, in some subgroups, treatment with pyridostigmine is detrimental; detailed genetic testing is required before starting therapy.

Pyridostigmine sometimes is used to treat orthostatic hypotension. It may also be of benefit in chronic axonal polyneuropathy.

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market